AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02245958 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.
Study NCT02626780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
Study NCT02821403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear lens with regular coating
Study NCT02821403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: regular coating lens with yellow tint
Study NCT02821403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear lens with blue-light blocking coating
Study NCT01855776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
Study NCT01855776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentives
Description: Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
Study NCT01855776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charitable Incentives
Description: Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
Study NCT01855776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.
Study NCT01855776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.
Study NCT00254202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Study NCT00254202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study NCT00254202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03331198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel)
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
Study NCT03331198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) + ibrutinib
Description: Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
Study NCT03331198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) + venetoclax
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
Study NCT04157517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion.
Study NCT04157517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.
Study NCT01540487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin/metformin(high dose)
Description: patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
Study NCT01540487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/metformin(low dose)
Description: patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
Study NCT00208169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study NCT05268783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Description: Quality of life questionnaire that has to be completed every 6 months
Study NCT05268783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-GI.NET21
Description: Quality of life questionnaire that has to be completed every 6 months
Study NCT05268783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Satisfaction survey
Description: Questionnaire regarding satisfaction of care that has to be completed on Day 1.
Study NCT00445172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 (mecobalamin)
Description: Intramuscular injection, mecobalamin twice a week.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FLUOROURACYL
Description: Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study NCT04032678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schiller Defigard Touch 7 - DGT7, Schiller Medical, France
Description: Cardioversion with a pulsed biphasic waveform
Study NCT04032678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA
Description: Cardioversion with a biphasic truncated exponential waveform
Study NCT03265496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical exam
Description: Clinical exam is performed before treatment start
Study NCT03265496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
Study NCT03265496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic exam
Description: Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
Study NCT03265496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1st line treatment
Description: 1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
Study NCT03265496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor evaluation
Description: Tumor evaluation will be performed every 3 cycles of chemotherapy
Study NCT03265496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
Study NCT01475383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03654746
Description: 20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
Study NCT01475383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: once daily dosing of placebo capsules following the dosing scheme described in 1.1.
Study NCT01475383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily dosing of placebo capsules following the dosing scheme described in 1.1
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FLUOROURACYL
Description: Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acide folinique
Description: 200 mg/m² if Elvorine
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acide folinique
Description: 200 mg/m² if Elvorine
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Study NCT01475383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-03654746
Description: 20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capécitabine
Description: For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capécitabine
Description: For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study NCT03355742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE
Description: Subjects who received XIENCE family stent systems will be included.
Study NCT03355742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
Study NCT02842580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
Study NCT01998802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator EBI-005
Study NCT01998802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT03768154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine + spontaneous effort
Description: without muscle paralysis in supine position
Study NCT03768154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine + paralysis
Description: administer muscle paralysis in supine position
Study NCT03768154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone + paralysis
Description: change the patient position from supine to prone with muscle paralysis
Study NCT03768154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone + spontaneous breathing
Description: cease the paralysis in supine position
Study NCT01547442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisan Aphakia Intraocular Lens
Description: Implantation of an intraocular lens
Study NCT01570361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
Study NCT01570361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Treatment
Description: Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
Study NCT04274010 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PillCamTM Crohn's capsule
Description: Capsule endoscopy for small and large bowel to assess Crohn's disease activity.
Study NCT04274010 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic resonance enterography
Description: MRI scan of small bowel to assess small bowel Crohn's disease activity.
Study NCT04274010 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ileo-colonoscopy
Description: Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.
Study NCT06732479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Skill Training Programme
Description: BST was administered in 3 sessions in a week on alternate days, each session lasting for an hour. Training was given in small groups consisting of 4-6 members. Parents were involved as co-therapists, and observed the training given by the researcher and practiced it at home with their children.~The training was carried out through the following steps:~1. Instruction- Involved teaching the location of private parts, difference between appropriate and inappropriate touch, safe and unsafe secrets, sexuality, self-protection skills (saying NO, move from situation, tell trusted person, report the person and situation.~2. Modelling- researcher, modelled, correct responses, and instructed to act in the unsafe situation using role play. Situations were presented using video.~3. Rehearsal-researcher presented situations using video and instructed to rehearse the skills until able to demonstrate the skill independently
Study NCT02540148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nova Oculus™ Micro-current electrical stimulation
Description: Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
Study NCT01094158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
Study NCT01094158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
Study NCT01094158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
Study NCT04144894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Shear Wave Elastography
Description: Advanced ultrasound technique
Study NCT06684574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic walking program
Description: The intervention is a defined program of Nordic walking and strengthening exercises for 10 weeks in a regimen of two days per week (two 75-minute sessions per week). In these sessions, they did Nordic walking three 5-minute breaks, where strength and proprioception exercises of the lower extremities were performed.
Study NCT06684574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational advise
Description: Patients in the control arm participated in a single session to advise them on the need for self-exercise.
Study NCT02220036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follistim
Description: Follicle stimulating hormone promotes recruitment of follicles for ovulation.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follistim
Description: Follicle stimulating hormone promotes recruitment of follicles for ovulation.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropins
Description: Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
Study NCT02069808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
Study NCT02069808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound guided needle aspiration of oocytes
Study NCT02069808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound guided needle aspiration of oocytes
Study NCT04237064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging